Bulk order Acrobiosystems for Chinese

Chinese

A-Z

SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA KitsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 spike mutantsNew
Others
Bispecific antibody targetsHot Targets for ADCsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot TNFSF proteinsHot VEGF proteinsHot CD47 proteins CD24 & Siglec-10 proteinsHot CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

Your Position: Home > SLAMF7

SLAMF7

SLAMF7 Molecule Information

Name:SLAM family member 7
Target Synonym:CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,Novel LY9 (Lymphocyte Antige

Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

SLAMF7 Protein Product ListCompare or Buy

Product> Filter Results

Cat. No.	Species	Product Description
SL7-HP2H3	Human	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation)
SL7-HF2H7	Human	FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-R52H7	Rhesus macaque	Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-M5252	Mouse	Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin
SL7-H82E0	Human	Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag
SL7-H5256	Human	Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-H5225	Human	Human SLAMF7 / CRACC / CD319 Protein, His Tag

SLAMF7 Part of Bioactivity data

SL7-HP2H3-Cell-based assay

FACS assay shows that recombinant Biotinylated FACS

1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).

Protocol

SL7-HF2H7-Cell-based assay

2e5 of Anti-SLAMF7 CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested)

Protocol

SL7-H5256-ELISA

Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 2 μg/mL (100 μL/well) can bind Humanized Anti-Human CS1 MAb with a linear range of 0.3-5 ng/mL (Routinely tested).

Protocol

SL7-H82E0-ELISA

Immobilized Humanized Anti-Human CS1 MAb at 1 μg/mL (100 μL/well) can bind Biotinylated Human SLAMF7, Avitag,His Tag (Cat. No. SL7-H82E0) with a linear range of 0.6-5 ng/mL (Routinely tested).

Protocol

SLAMF7 Molecule Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

SLAMF7 Molecule Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 References

SLAMF7 Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Elotuzumab	PDL-063; HuLuc-63; BMS-901608	Approved	Abbvie Inc, Bristol-Myers Squibb Company	Empliciti	Japan	Multiple Myeloma	s:28:"Bristol-Myers Squibb Company";	2015-11-30	Smoldering Multiple Myeloma; Multiple Myeloma	Details

SLAMF7 Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
CS1 Targeted CAR T-cells (Yake Biotechnology)		Phase 1 Clinical	Yake Biotechnology Ltd	Multiple Myeloma	Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)		Clinical	Wuhan Bio-Raid Biotechnology, Tongji Hospital	Hematologic Neoplasms	Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)		Phase 1 Clinical	Icell Gene Therapeutics	Multiple Myeloma	Details
UCART-CS1	UCART-38; UCART-CS1	Phase 1 Clinical	Cellectis	Multiple Myeloma	Details